Board of Directors Approved Financial Statements For the Year Ended December 31, 2021
· Issued by TSH Biopharm Corp. Ltd.
Close
Today's Information
Provided by: TSH Biopharm Corporation Limited
SEQ_NO
1
Date of announcement
2022/03/04
Time of announcement
16:41:26
Subject
TSH Board of Directors Approved Financial Statements
For the Year Ended December 31, 2021
Date of events
2022/03/04
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/04
2.Date of the audit committee approved:2022/03/04
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01-2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):413,483
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):247,358
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):55,615
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):61,549
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):47,108
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):47,108
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.23
11.Total assets end of the period (thousand NTD):1,169,426
12.Total liabilities end of the period
(thousand NTD):85,800
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,083,626
14.Any other matters that need to be specified:None
